Sichuan Kelun Pharmaceutical Co.Ltd(002422) 4 on the evening of April 10, the annual report of 2021 was released. The company achieved an operating revenue of 17.277 billion yuan in 2021, with a year-on-year increase of 4.94%; The net profit attributable to the shareholders of the listed company was 1.103 billion yuan, a year-on-year increase of 32.94%; The basic earnings per share is 0.78 yuan. The company plans to distribute a cash dividend of 4.26 yuan (including tax) to all shareholders for every 10 shares.
For the reasons for performance changes, the annual report shows that in 2021, although still affected by the fluctuation of the epidemic, the company made every effort to expand the market of infusion and non infusion preparations, and the operating revenue and profit increased year-on-year. At the same time, the generic drugs approved by the company in recent years continued to increase in volume. The company also actively optimized the financing structure, reduced the average financing interest rate and financial expenses.
In terms of R & D and innovation, Sichuan Kelun Pharmaceutical Co.Ltd(002422) since 2013, more than 8.5 billion yuan has been invested in R & D and innovation. Over the past nine years, Sichuan Kelun Pharmaceutical Co.Ltd(002422) launched the research of more than 300 drugs facing the foreign market in China, including 276 generic and improved innovative drugs with cluster, difficulty, characteristics and cost advantages, and 63 innovative small molecule and biotechnology drugs with me better characteristics.
In 2021, Sichuan Kelun Pharmaceutical Co.Ltd(002422) concentrate resources to promote projects with competitive advantages and market value. As of December 31, 2021, the company has innovated 55 small molecule and small molecule projects (including 25 innovative small molecule drugs and 30 biological macromolecular drugs), mainly focusing on tumors. At the same time, it has arranged the fields of liver diseases, cardiovascular diseases, anesthesia and analgesia, autoimmunity and other diseases, formed the advantages of disease cluster and product iteration, mainly promoted 12 innovative clinical projects, and developed 9 innovative preclinical stage projects and more than 30 drug discovery stage projects at the same time.
According to the annual report, in 2021 Sichuan Kelun Pharmaceutical Co.Ltd(002422) put the quality first strategy and cost first strategy firmly into the generic drug R & D system, guided by the market, strengthened cost accounting, and achieved 33 approved production and 3 approved clinical. During the reporting period, Sichuan Kelun Pharmaceutical Co.Ltd(002422) there were 30 generic drugs declared for production. With the approval of subsequent varieties, it will further enhance the value of Sichuan Kelun Pharmaceutical Co.Ltd(002422) tumor, bacterial infection, cardio cerebrovascular, anesthesia and analgesia and other product lines, and enter the field of COPD for the first time. In the fifth batch of national centralized procurement in 2021, Sichuan Kelun Pharmaceutical Co.Ltd(002422) totally 11 products won the bid, and the number of winning bids ranked first. Sichuan Kelun Pharmaceutical Co.Ltd(002422) has become one of the top suppliers of national centralized procurement.
In the business plan, Sichuan Kelun Pharmaceutical Co.Ltd(002422) said that in 2022, the company's generic drug research will continue to adhere to the clinical and market value oriented and total cost leading strategy, continue to increase the layout and investment of complex raw materials, complex preparations, NDDs and improvement and innovation projects on the basis of establishing the advantages of product clusters, explore the blue ocean field, and focus on continuously promoting the construction of fine control system in the whole process to ensure the planned output of the project, Maximize the output value of the project.
In Sichuan Kelun Pharmaceutical Co.Ltd(002422) 2022, generic drugs are expected to receive 20 -25 items and 32 items of -35 items, including diabetes, anesthesia, diagnostic radiography, men's and women's specialties, parenteral nutrition, anti infection, respiratory diseases, cancer, cardiovascular, ophthalmic, psychiatric and other diseases, as well as the declaration and production of varieties of high technology difficulty platforms such as membrane agents and liposomes.
